This presentation and course are substantially more consistent with an IgG4 paranodal/nodal antibody-associated autoimmune nodopathy (most likely anti-CNTN1, or a closely related CNTN1/Caspr1-complex nodopathy) causing a combined nodo-glomerular syndrome, rather than classical CIDP coexisting with an unrelated, antigen-negative membranous nephropathy. Both the "treatment-resistant CIDP" label and the consultant's conclusion that a nonimmune neuropathy has been "established" are premature.
Why autoimmune nodopathy fits better than CIDP
Autoimmune nodopathies meet standard electrodiagnostic criteria for "demyelinating" polyneuropathy (slowed conduction, prolonged distal latencies, absent F waves, conduction block) because antibodies disrupt the paranodal axoglial junction and sodium-channel clustering — not because of true segmental demyelination. This explains why this patient's electrophysiology was independently confirmed as meeting CIDP criteria, yet the course behaves nothing like typical CIDP. [1-2]
The clinical phenotype — subacute onset, severe sensory ataxia with marked postural/action tremor, finger drift and dysmetria worse with eyes closed, poor response to IVIG, only partial/transient response to plasma exchange, and concurrent nephrotic-range proteinuria — is the classic description of CNTN1/Caspr1-related autoimmune nodopathy (AN). IgG4 antibodies do not fix complement or bind Fc receptors well, which accounts for the poor IVIG and steroid response despite the patient's subjective "energy" after infusions. [1-4]
Nerve-conduction studies in anti-CNTN1/Caspr1 AN characteristically show early, prominent axonal features (falling motor amplitudes, active denervation) superimposed on demyelinating-range parameters, exactly as seen on this patient's repeat studies. [2]
Why the sural nerve biopsy does not exclude an immune cause
Ultrastructural studies in CNTN1- and NF155-associated nodopathy show injury confined to the paranode — axoglial detachment — without true demyelination, remyelination, or macrophage-mediated myelin stripping on routine light microscopy. [2] A sural nerve biopsy showing axonal loss and active axonal degeneration with "little inflammation" is therefore the expected finding in this disease, not evidence against an immune mechanism. Reading this biopsy as proof of a "nonimmune" axonal neuropathy conflates a lack of classical demyelinating histology with a lack of autoimmunity.
Why the negative antibody panel is unreliable
The nodal/paranodal panel was drawn the morning after the fifth plasma exchange and after a corticosteroid course — precisely the conditions expected to lower a pathogenic IgG4 autoantibody titre below the assay's detection threshold, since apheresis directly removes circulating IgG and corticosteroids suppress antibody production. [5-6] A single post-treatment negative result cannot exclude autoimmune nodopathy. The pretreatment serum held in the biobank — collected before any immunoglobulin, steroid, or plasma exchange — is the only specimen that can reliably answer this question and should be tested for CNTN1, Caspr1, CNTN1/Caspr1-complex, NF155, and pan-neurofascin IgG (with IgG4 subclassing) using a validated cell-based or multiplex flow-cytometry assay. [7-9]
The renal findings support a single unifying disease
Membranous nephropathy with IgG4-predominant granular deposits, subepithelial electron-dense deposits, and negative PLA2R/THSD7A staining (with negative pretreatment serum anti-PLA2R) in a patient with a concurrent paranodal-type neuropathy is the described phenotype of CNTN1-associated nephropathy: CNTN1 is expressed in both peripheral nerve paranodes and glomeruli, and anti-CNTN1 IgG4 immune complexes deposit in the glomerular basement membrane, producing membranous nephropathy indistinguishable from primary PLA2R-negative disease on light and electron microscopy. [10-11] The fact that heavy proteinuria preceded any immunotherapy argues against a drug- or treatment-related nephropathy and favours a shared autoimmune process. If tissue remains, immunostaining or IgG elution from the kidney biopsy for CNTN1 could directly confirm this link, as has been done in prior case series. [11]
Other diagnoses still worth excluding
Diabetic sensorimotor polyneuropathy — the tempo (symmetric weakness to wheelchair dependence in under five months), proximal involvement, areflexia, and demyelinating-range conduction changes are far too aggressive for diabetic neuropathy, and his glycaemic control has been good.
POEMS syndrome and monoclonal gammopathy-associated neuropathy/nephropathy — reasonably excluded by normal serum/urine immunofixation, normal free light-chain ratio, and no organomegaly on CT, though these should be reconsidered if serology changes.
Occult malignancy-associated (paraneoplastic) membranous nephropathy — no malignancy identified on CT chest/abdomen/pelvis to date; surveillance should continue given his age.
Classical antibody-negative CIDP with coincidental primary membranous nephropathy remains possible but is a less parsimonious explanation than a single CNTN1-mediated nodo-glomerular syndrome, given the shared timing, IgG4 predominance, and PLA2R-negative renal pathology.
Feature Typical CIDP Anti-CNTN1/Caspr1 autoimmune nodopathy This patient Onset/course Chronic, >8 weeks, relapsing or progressive Often subacute, aggressive Subacute, wheelchair-dependent within months Sensory ataxia/tremor Variable Prominent, often severe Severe ataxia, coarse tremor CSF protein Elevated Markedly elevated 2.1 g/L Response to IVIG/steroids Usually good Typically poor No sustained benefit Response to plasma exchange Variable Often more effective (removes antibody) Modest, transient benefit Nerve conduction Demyelinating Demyelinating-range with early axonal loss Demyelinating-range criteria met, falling amplitudes, active denervation Nerve biopsy Variable demyelination/remyelination Paranodal axoglial detachment, often looks "axonal" on light microscopy Axonal loss, no inflammation or macrophage-mediated demyelination Nephrotic syndrome Rare, reported with nodal antibodies Characteristic of anti-CNTN1 Present, PLA2R/THSD7A-negative, IgG4-predominant MN Response to rituximab Inconsistent Good Not yet trialled Next steps
Send the banked pretreatment serum for CNTN1, Caspr1, CNTN1/Caspr1-complex, NF155, and pan-neurofascin antibodies with IgG4 subclassing via a validated assay before accepting the current post-treatment result as definitive. [7-9]
Consider CNTN1 immunostaining or IgG elution on the archived renal biopsy tissue to directly link the glomerular and neural disease. [11]
Hold further IVIG and corticosteroid courses, which have shown no sustained benefit and are mechanistically unlikely to help an IgG4-mediated process. [1-2]
If antibody positivity is confirmed (or if clinical suspicion remains high despite a technically compromised negative result), proceed to rituximab (anti-CD20 B-cell depletion), which has reported efficacy for both the neuropathy and the associated membranous nephropathy in this syndrome, with neurological and renal improvement tracking antibody suppression. [2-3][9-10][12]
Continue supportive nephrotic syndrome management (diuretics, ACE inhibitor/ARB if tolerated, thromboprophylaxis given albumin 21 g/L) and maintain malignancy surveillance given his age.
Manage this jointly between neurology and nephrology given the unifying diagnosis.
Matched clinical trials
Clinical Trials Chronic Inflammatory Demyelinating Polyneuropathy · CNTN1 antibody · rituximab 6 trials 6 trials
Relevance Filters
Matches disease Examining Engagement Trends Among Participants in Peripheral Neuropathy Clinical Research
Not yet recruiting Sponsor: Power Life Sciences Inc.
Updated: 29 Mar 2024
Matches disease Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
Recruiting Sponsor: Sanofi
Updated: 24 Jul 2026
Highly relevant · Matches disease · Basket trial Biorepository and Registry for Plasma Exchange Patients
Recruiting Sponsor: Charles M Knudson
Updated: 20 May 2025
Matches disease · biomarker · Basket trial Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
Recruiting Phase 1 Sponsor: Kite, A Gilead Company
Updated: 19 Oct 2026
Matches disease · Basket trial Investigational Use of Neuromuscular Ultrasound
Recruiting Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Updated: 17 Sept 2026
Matches disease · Basket trial Safety of Cultured Allogeneic Adult Umbilical Cordor Placental Derived Stem Cells Exosomes for Trigeminal Neuralgia
Recruiting Phase 1 Sponsor: The Foundation for Orthopaedics and Regenerative Medicine
Updated: 20 Oct 2026
© OpenStreetMap · CARTO The search returned 6 available trials. Among the top trials in the displayed dashboard, a phase 1 study of KITE-363 (a CD19/CD20-directed therapy given with lymphodepleting chemotherapy) is enrolling patients with autoimmune neurologic disease refractory to usual treatment, which could be relevant if B-cell depletion with rituximab fails or is contraindicated. A CIDP real-world treatment outcomes registry and a plasma-exchange biorepository/registry are also recruiting and could be suitable for banking samples and tracking this patient's course. The other listed trials (engagement-trends study, neuromuscular ultrasound study, trigeminal neuralgia stem-cell study) are not directly relevant to this case.
Would it help to know whether the patient has had anti-PLA2R and paranodal antibody testing repeated now, further out from plasma exchange and steroids, or whether the biobanked pretreatment serum is still being processed?
Is the pretreatment banked serum sample already being sent for CNTN1/Caspr1/NF155/pan-neurofascin antibody testing, or would it help to outline exactly how to request this (assay type, subclass testing) from a neuroimmunology reference laboratory?